Cumberland Pharmaceuticals (CPIX) EBT Margin (2010 - 2026)
Cumberland Pharmaceuticals' (CPIX) quarterly EBT Margin came in at 1862.51% in Q2 2026, down 107666.0% year-over-year from N/an in Q2 2025, and down 5321.31% quarter-over-quarter from 34.36% in Q1 2026.
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) EBT Margin (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has disclosed EBT Margin across 17 years of filings, most recently posting 1862.51% for Q2 2026.
- In Q2 2026, EBT Margin fell 107666.0% year-over-year to 1862.51%; the TTM figure through Jun 2026 stood at 30.62% (down 1410.0% YoY), while the FY2025 annual figure was 6.31%, up 1076.0% from the prior year.
- EBT Margin came in at 1862.51% for Q2 2026 at Cumberland Pharmaceuticals, down from 34.36% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 10.7% in Q1 2025 to a low of 1862.51% in Q2 2026.
- Average EBT Margin over 5 years is 161.0%, with a median of 14.99% recorded in 2022.
- Year-over-year, EBT Margin surged 4834 bps in 2024 and sank 107666 bps in 2026.
- Over 5 years, EBT Margin stood at 26.43% in 2022, then tumbled by 154 bps to 67.11% in 2023, then surged by 72 bps to 18.77% in 2024, then jumped by 46 bps to 10.18% in 2025, then plunged by 18200 bps to 1862.51% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 1862.51% in Q2 2026, 34.36% in Q1 2026, and 10.18% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.38 Bn | 624.62 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 443.13 Bn | 436.56 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 365.40 Bn | 358.26 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 266.79 Bn | 259.10 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -4.34% |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | 12.17% |
| 7 | Revolution Medicines | 43.92 Bn | 43.92 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 44.89% |
| 9 | United Therapeutics | 21.55 Bn | 18.88 Bn | 683.80 Mn | 47.58% |
| 10 | Cumberland Pharmaceuticals | 95.51 Mn | 91.65 Mn | - | -1,862.51% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,862.51% |
| Mar 31, 2026 | -34.36% |
| Dec 31, 2025 | -10.18% |
| Sep 30, 2025 | -23.44% |
| Jun 30, 2025 | -785.85% |
| Mar 31, 2025 | 10.70% |
| Dec 31, 2024 | -18.77% |
| Sep 30, 2024 | -16.79% |
| Jun 30, 2024 | -11.08% |
| Mar 31, 2024 | -22.25% |
| Dec 31, 2023 | -67.11% |
| Sep 30, 2023 | -10.47% |
| Jun 30, 2023 | 7.98% |
| Mar 31, 2023 | 1.94% |
| Dec 31, 2022 | -26.43% |
| Sep 30, 2022 | -3.65% |
| Jun 30, 2022 | -13.18% |
| Mar 31, 2022 | -12.49% |
| Dec 31, 2021 | -52.59% |
| Sep 30, 2021 | -19.52% |